Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8048603 | 0.86 | ALDH1A1 (0.61) | MYCNR4A1MLYCDALDH1A1ENPP2 | |
| SCHEMBL8690764 | 0.84 | ENPP2 (0.45) | MYCNR4A1MLYCDRBP4ALDH1A1 | |
| SCHEMBL594621 | 0.81 | L3MBTL1 (0.57) | MYCNR4A1ALDH1A1ENPP2ALOX15 | |
| SCHEMBL3808106 | 0.80 | ALDH1A1 (0.70) | MYCNR4A1ALDH1A1ENPP2ALOX15 | |
| SCHEMBL29467270 | 0.79 | NPC1 (0.68) | MYCNR4A1ALDH1A1ENPP2ALOX15 | |
| SCHEMBL2492855 | 0.79 | NPC1 (0.68) | MYCNR4A1ALDH1A1ENPP2ALOX15 | |
| SCHEMBL110679 | 0.79 | GPR119 (0.54) | MYCRBP4ALDH1A1ENPP2 | |
| SCHEMBL9114338 | 0.79 | ALDH1A1 (0.58) | MYCNR4A1RBP4ALDH1A1ENPP2 | |
| SCHEMBL25387883 | 0.79 | MAPT (0.41) | MYCNR4A1MLYCDRBP4ALDH1A1 | |
| SCHEMBL11093160 | 0.78 | GRIN2D (0.43) | RBP4ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260454-B2 | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20140296169-A1 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296169-A1 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TGM2, TGM1, TGM6 | MYC 4884/4885NR4A1 3939/4885MLYCD 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.